Dr Nienke Lubben
Nienke is a European and UK Chartered Patent Attorney with considerable experience in the biotechnology and life sciences fields. She has particular interest in point of care diagnostics, having represented several clients in this area.
Nienke's portfolio encompasses a diverse range of biological subject matter including: personalised medicine, biomarkers, biosimilars, antibodies, immunology, therapeutics, cell biology, biotechnology, enzymology, diagnositics and biopharmaceuticals. She handles all patent related matters including: preparing patent applications, prosecuting patent applications before the EPO and UKIPO, managing worldwide patent prosecution, strategic reviews, due diligence, and validity opinions.
Nienke has considerable experience working with universities and spin-out companies and can bring a depth of commercially relevant advice from her experience in working for a start-up biotech company prior to entering the profession. Nienke also works with SMEs and large multinational companies. Her pragmatic advice is appropriately tailored to her client's individual needs.
Nienke has represented clients before the Oppositions Division of the EPO and has a particular interest in opposition matters. Her ability to quickly assimilate and utilise scientific literature to the benefit of her clients is a key strength during oral proceedings before both the Opposition Division and the Boards of Appeal of the EPO.
Nienke qualified as a Patent Attorney in 2012 and was awarded the Strode Prize for obtaining the highest mark in the UK finals law exam, P2. She also holds a Post-Graduate Certificate in Intellectual Property Law from the Queen Mary, University of London, obtained with distinction. She graduated with a First Class Honours degree in Biological Sciences (Genetics) from the University of Leicester and was awarded the Graduate of the Year Prize for obtaining the highest degree mark in her class. After graduating, Nienke worked for two years as an industrial research scientist on novel and innovative platform technologies in the field of diagnostics.
Nienke returned to academia to obtain a PhD in Clinical Biochemistry from the University of Cambridge. Her doctoral research focussed on the cellular mechanisms used by HIV-1 Nef to evade the host immune system and led to three publications. Her PhD project involved a wide range of techniques including cell culture, flow cytometry, cloning, protein expression and immunofluorescence. She has also carried out academic research in the fields of medical genetics, cell cycle regulation, biochemistry and cell biology.